Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Zymeworks Inc. - Common Stock (NQ:ZYME)

19.00 +0.38 (+2.04%)
Streaming Delayed Price Updated: 11:39 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zymeworks Inc. - Common Stock

Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit
Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, including ZW191 and ZW251. 
Via Benzinga
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer. 
Via Stocktwits
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)
 
Via Benzinga
Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)
 
Via Benzinga
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Which stocks are moving after the closing bell on Friday?
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines. 
Via Stocktwits
TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy
The research firm expects key clinical data in late 2025 and sees Ziihera royalties funding pipeline development. 
Via Stocktwits
What Analysts Are Saying About Zymeworks Stock
 
Via Benzinga
Navigating 6 Analyst Ratings For Zymeworks
 
Via Benzinga
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves. 
Via Benzinga
Topics Earnings
Earnings Scheduled For March 5, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Zymeworks in Focus for Insider Activity: Catalysts Ahead
Zymeworks' insider EcoR1 Capital is buying shares ahead of expected catalysts in 2025 that could drive the stock price to multiyear highs. 
Via MarketBeat
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone. 
Via Benzinga
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.